PMC:5848821 / 13247-14184 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/5848821","sourcedb":"PMC","sourceid":"5848821","source_url":"https://www.ncbi.nlm.nih.gov/pmc/5848821","text":"Multimodal therapy\nNeoadjuvant therapy was administered in 67 patients (62.2%), pseudo-neoadjuvant therapy before surgery for recurrence in 15 patients (33.3%), adjuvant therapy in 68 patients (63.6%) and pseudo-adjuvant therapy after surgery for recurrence in 10 patients (22.2%), respectively (Table 2). Neo- and pseudo-neoadjuvant PAC ChT (planned protocol: cisplatin 50 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2) was administered in 45 patients of the 76 (59.2%) patients who received ChT. For induction therapy (n = 65), the mean number of administered ChT cycles was 4.15 (median 4, range 2–8).\nRadiotherapy was administered in a neoadjuvant (8 patients), pseudo-neoadjuvant (1 patient), adjuvant (63 patients) or pseudo-adjuvant (5 patients) setting. The administered mean radiation dose was 40.9 G [median 45 G, range 20–56 G] for neoadjuvant therapy and 50.3 G [median 50 G, range 24–60 G] for adjuvant therapy.","divisions":[{"label":"title","span":{"begin":0,"end":18}},{"label":"p","span":{"begin":19,"end":617}}],"tracks":[]}